Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.

Harrison TE. et al, (2024), EMBO Mol Med

Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.

Barrett JR. et al, (2024), Cell

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.

Wang LT. et al, (2024), Cell

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

King LDW. et al, (2024), Cell Rep Med, 5

Structure-guided design of aPlasmodium vivaxDuffy binding protein-based vaccine immunogen

Barber NM. et al, (2024)

A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies.

Donnellan FR. et al, (2024)

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.

Williams BG. et al, (2024), Nat Commun, 15

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.

Mertens JE. et al, (2024), Vaccine

Evaluation of Precision of thePlasmodium knowlesiGrowth Inhibition Assay forPlasmodium vivaxDuffy-Binding Protein-based Malaria Vaccine Development

Mertens JE. et al, (2024)

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Martinez FJ. et al, (2024), NPJ Vaccines, 9

Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies

King LDW. et al, (2024)

Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5

Harrison T. et al, (2024)

The PfRCR complex bridges malaria parasite and erythrocyte during invasion.

Farrell B. et al, (2023), Nature

Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein.

Watson QD. et al, (2023), Malar J, 22

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.

Mitsi E. et al, (2023), Nat Commun, 14

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

Wang LT. et al, (2023)

Erythrocyte invasion-neutralising antibodies prevent Plasmodium falciparum RH5 from binding to basigin-containing membrane protein complexes.

Jamwal A. et al, (2023), Elife, 12

Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype

Barrett JR. et al, (2023)

Cellular iron governs the host response to malaria.

Wideman SK. et al, (2023), PLoS Pathog, 19

Load More

Include forthcoming?